ClinicalTrials.gg
CompletedNCT01743677Updated Sep 16, 2020Results posted

CP-690,550 Thorough QTc Study

A Phase 1 interventional study of CP-690,550 and Placebo in Healthy, sponsored by Pfizer. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Pfizer · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 4 years 11 months after the study started (first participant enrolled Oct 2007, registered Oct 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

ICH E14 recommends that a thorough QT/QTc (TQT) study should be performed to determine whether intensive monitoring of QT interval in target patient populations is required during later stages of development. The current study is designed to ascertain whether CP-690,550 is associated with QTc prolongation.

Read the detailed description

The current study is designed to ascertain whether CP-690,550 is associated with QTc prolongation

02

Conditions studied

  • Healthy

Keywords

  • TQT study
  • CP-690
  • 550
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects between ages of 18 and 55 years, inclusive.
  • (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

  • Use of tobacco- or nicotine-containing products in excess of equivalent of 5 cigarettes per day.
  • 12-lead demonstrating >450 msec or other abnormalities at Screening.
  • History of risk factors for QT prolongation or torsades de pointes.
  • Pregnant or nursing women; women of unwilling or unable to use an acceptable method of nonhormonal from at least 14 days prior to first dose until completion of follow-up.
  • Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to first dose of trial medication.
  • Any clinically significant infections within past 3 months or evidence of infection in past 7 days.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    CP-690,550 100 mg

    Drug: CP-690,550

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Moxifloxacin hydrochloride

    Drug: Moxifloxacin

Interventions

  • Single dose 100 mg (5 x 20 mg tablets)

  • DrugPlacebo

    Single dose placebo tablets (5 tablets)

  • Single dose Avelox 400 mg tablet

06

What researchers measure

Primary outcomes

  1. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose

    Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as Least Squares (LS) mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 0.25 hour post-dose

  2. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.5 Hour Post-Dose

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 0.5 hour post-dose

  3. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 1 Hour Post-Dose

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 1 hour post-dose

  4. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 2 Hours Post-Dose

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 2 hours post-dose

  5. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 4 Hours Post-Dose

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 4 hours post-dose

  6. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 8 Hours Post-Dose

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 8 hours post-dose

  7. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 12 Hours Post-Dose

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 12 hours post-dose

  8. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 16 Hours Post-Dose

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 16 hours post-dose

  9. Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 24 Hours Post-Dose

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 24 hours post-dose

Secondary outcomes

  1. Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (moxifloxacin minus Placebo, baseline-adjusted).

    Time frame: 2 hours post-dose

  2. Mean Time-Matched Difference in QTcB Intervals Between CP-690,550 Compared to Placebo

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Bazett's formula (QTcB = QT divided by square root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

    Time frame: 0.25, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours post-dose

  3. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-690,550

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  4. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-690,550

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  5. Maximum Observed Plasma Concentration (Cmax) of CP-690,550

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  6. Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  7. Plasma Decay Half-Life (t1/2) of CP-690,550

    Plasma decay half-life is the time measured for the plasma concentration of drug to decrease by one half.

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  8. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of CP-690,550 by Cytochrome P450 2C19 (CYP2C19) Genotype

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. AUC (0 - ∞) categorized by genotype into poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  9. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-690,550 by CYP2C19 Genotype

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. AUClast categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  10. Maximum Observed Plasma Concentration (Cmax) of CP-690,550 by CYP2C19 Genotype

    Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. Cmax categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  11. Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-690,550 by CYP2C19 Genotype

    Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. Tmax categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

  12. Plasma Decay Half-Life (t1/2) of CP-690,550 by CYP2C19 Genotype

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. t1/2 categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

    Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose

07

Results

Posted Sep 16, 2020

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneCP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mgCP-690,550 100 mg Then Moxifloxacin 400 mg Then PlaceboPlacebo Then CP-690,550 100 mg Then Moxifloxacin 400 mgPlacebo Then Moxifloxacin 400 mg Then CP-690,550 100 mgMoxifloxacin 400 mg Then CP-690,550 100 mg Then PlaceboMoxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg
Started101010101010
Completed101010101010
Not completed000000
Washout Period 1 (at Least 7 Days)
Participant flow — Washout Period 1 (at Least 7 Days)
MilestoneCP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mgCP-690,550 100 mg Then Moxifloxacin 400 mg Then PlaceboPlacebo Then CP-690,550 100 mg Then Moxifloxacin 400 mgPlacebo Then Moxifloxacin 400 mg Then CP-690,550 100 mgMoxifloxacin 400 mg Then CP-690,550 100 mg Then PlaceboMoxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg
Started101010101010
Completed101010101010
Not completed000000
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneCP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mgCP-690,550 100 mg Then Moxifloxacin 400 mg Then PlaceboPlacebo Then CP-690,550 100 mg Then Moxifloxacin 400 mgPlacebo Then Moxifloxacin 400 mg Then CP-690,550 100 mgMoxifloxacin 400 mg Then CP-690,550 100 mg Then PlaceboMoxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg
Started101010101010
Completed101010101010
Not completed000000
Washout Period 2 (at Least 7 Days)
Participant flow — Washout Period 2 (at Least 7 Days)
MilestoneCP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mgCP-690,550 100 mg Then Moxifloxacin 400 mg Then PlaceboPlacebo Then CP-690,550 100 mg Then Moxifloxacin 400 mgPlacebo Then Moxifloxacin 400 mg Then CP-690,550 100 mgMoxifloxacin 400 mg Then CP-690,550 100 mg Then PlaceboMoxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg
Started101010101010
Completed101010101010
Not completed000000
Third Intervention Period
Participant flow — Third Intervention Period
MilestoneCP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mgCP-690,550 100 mg Then Moxifloxacin 400 mg Then PlaceboPlacebo Then CP-690,550 100 mg Then Moxifloxacin 400 mgPlacebo Then Moxifloxacin 400 mg Then CP-690,550 100 mgMoxifloxacin 400 mg Then CP-690,550 100 mg Then PlaceboMoxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg
Started101010101010
Completed101010101010
Not completed000000

Outcome measures

PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose

Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as Least Squares (LS) mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
0.25 hour post-dose
Reported as:
Least squares mean · milliseconds (msec)
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose
milliseconds (msec)CP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose416.48 ± 0.8823417.77 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: -1.29 · 90% CI -3.15 to 0.56
PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.5 Hour Post-Dose

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
0.5 hour post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.5 Hour Post-Dose
msecCP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.5 Hour Post-Dose414.70 ± 0.8823416.12 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: -1.42 · 90% CI -3.28 to 0.43
PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 1 Hour Post-Dose

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
1 hour post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 1 Hour Post-Dose
msecCP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 1 Hour Post-Dose414.69 ± 0.8823416.98 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: -2.29 · 90% CI -4.15 to -0.44
PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 2 Hours Post-Dose

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
2 hours post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 2 Hours Post-Dose
msecCP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 2 Hours Post-Dose413.70 ± 0.8823415.05 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: -1.35 · 90% CI -3.21 to 0.50
PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 4 Hours Post-Dose

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
4 hours post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 4 Hours Post-Dose
msecCP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 4 Hours Post-Dose416.83 ± 0.8823415.76 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 1.08 · 90% CI -0.78 to 2.93
PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 8 Hours Post-Dose

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
8 hours post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 8 Hours Post-Dose
msecCP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 8 Hours Post-Dose409.25 ± 0.8823408.39 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 0.86 · 90% CI -1.00 to 2.71
PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 12 Hours Post-Dose

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
12 hours post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 12 Hours Post-Dose
msecCP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 12 Hours Post-Dose411.39 ± 0.8823410.24 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 1.15 · 90% CI -0.71 to 3.00
PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 16 Hours Post-Dose

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
16 hours post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 16 Hours Post-Dose
msecCP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 16 Hours Post-Dose415.87 ± 0.8823413.72 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 2.15 · 90% CI 0.29 to 4.00
PrimaryMean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 24 Hours Post-Dose

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
24 hours post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 24 Hours Post-Dose
msecCP-690,550 100 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 24 Hours Post-Dose412.53 ± 0.8823411.18 ± 0.8823
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 1.35 · 90% CI -0.50 to 3.21
SecondaryMean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (moxifloxacin minus Placebo, baseline-adjusted).

Time frame:
2 hours post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo
msecMoxifloxacin 400 mgPlacebo
Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo426.34 ± 0.8823415.05 ± 0.8823
Statistical analysis
  • Moxifloxacin 400 mg vs Placebo · Least squares mean difference: 11.29 · 90% CI 9.62 to 12.96
SecondaryMean Time-Matched Difference in QTcB Intervals Between CP-690,550 Compared to Placebo

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Bazett's formula (QTcB = QT divided by square root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).

Time frame:
0.25, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours post-dose
Reported as:
Least squares mean · msec
Mean Time-Matched Difference in QTcB Intervals Between CP-690,550 Compared to Placebo
msecCP-690,550 100 mgPlacebo
0.25 Hour Post-Dose416.40 ± 1.1139416.24 ± 1.1139
0.5 Hour Post-Dose416.69 ± 1.1139414.91 ± 1.1139
1 Hour Post-Dose417.98 ± 1.1139414.99 ± 1.1139
2 Hours Post-Dose414.54 ± 1.1139413.46 ± 1.1139
4 Hours Post-Dose417.26 ± 1.1139415.10 ± 1.1139
8 Hours Post-Dose412.91 ± 1.1139412.86 ± 1.1139
12 Hours Post-Dose416.76 ± 1.1139416.27 ± 1.1139
16 Hours Post-Dose416.44 ± 1.1139414.33 ± 1.1139
24 Hours Post-Dose413.93 ± 1.1139413.14 ± 1.1139
Statistical analysis
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 0.16 · 90% CI -2.11 to 2.44
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 1.78 · 90% CI -0.49 to 4.06
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 2.99 · 90% CI 0.71 to 5.26
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 1.08 · 90% CI -1.19 to 3.36
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 2.16 · 90% CI -0.11 to 4.44
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 0.05 · 90% CI -2.22 to 2.33
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 0.49 · 90% CI -1.79 to 2.76
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 2.10 · 90% CI -0.17 to 4.38
  • CP-690,550 100 mg vs Placebo · Least squares mean difference: 0.79 · 90% CI -1.49 to 3.06
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-690,550

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-690,550
nanogram*hour/milliliter (ng*hr/mL)CP-690,550 100 mg
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-690,5502682.6 ± 778.15
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-690,550

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-690,550
ng*hr/mLCP-690,550 100 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-690,5502669.7 ± 771.02
SecondaryMaximum Observed Plasma Concentration (Cmax) of CP-690,550
Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of CP-690,550
nanogram/milliliter (ng/mL)CP-690,550 100 mg
Maximum Observed Plasma Concentration (Cmax) of CP-690,550563.5 ± 199.23
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550
Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550
hoursCP-690,550 100 mg
Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,5501.000 (0.30 to 4.08)
SecondaryPlasma Decay Half-Life (t1/2) of CP-690,550

Plasma decay half-life is the time measured for the plasma concentration of drug to decrease by one half.

Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2) of CP-690,550
hoursCP-690,550 100 mg
Plasma Decay Half-Life (t1/2) of CP-690,5503.284 ± 0.4871
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of CP-690,550 by Cytochrome P450 2C19 (CYP2C19) Genotype

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. AUC (0 - ∞) categorized by genotype into poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of CP-690,550 by Cytochrome P450 2C19 (CYP2C19) Genotype
ng*hr/mLCP-690,550 100 mg
Poor Metabolizer3127.5 ± 373.18
Extensive Metabolizer2683.5 ± 787.75
Ultra Extensive Metabolizer1677.7 ± 637.68
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-690,550 by CYP2C19 Genotype

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. AUClast categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-690,550 by CYP2C19 Genotype
ng*hr/mLCP-690,550 100 mg
Poor Metabolizer3114.3 ± 366.68
Extensive Metabolizer2670.2 ± 780.41
Ultra Extensive Metabolizer1673.1 ± 636.30
SecondaryMaximum Observed Plasma Concentration (Cmax) of CP-690,550 by CYP2C19 Genotype

Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. Cmax categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of CP-690,550 by CYP2C19 Genotype
ng/mLCP-690,550 100 mg
Poor Metabolizer647.4 ± 281.69
Extensive Metabolizer565.0 ± 185.62
Ultra Extensive Metabolizer346.9 ± 214.25
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of CP-690,550 by CYP2C19 Genotype

Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. Tmax categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-690,550 by CYP2C19 Genotype
hoursCP-690,550 100 mg
Poor Metabolizer0.500 (0.30 to 4.03)
Extensive Metabolizer1.000 (0.30 to 4.08)
Ultra Extensive Metabolizer2.000 (2.00 to 2.00)
SecondaryPlasma Decay Half-Life (t1/2) of CP-690,550 by CYP2C19 Genotype

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. t1/2 categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.

Time frame:
0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2) of CP-690,550 by CYP2C19 Genotype
hoursCP-690,550 100 mg
Poor Metabolizer3.005 ± 0.3566
Extensive Metabolizer3.320 ± 0.5006
Ultra Extensive Metabolizer3.201 ± 0.1821

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 100 mg—0/60 (0%)32/60 (53.3%)
Placebo—0/60 (0%)6/60 (10%)
Moxifloxacin—0/60 (0%)10/60 (16.7%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventCP-690,550 100 mgPlaceboMoxifloxacin
NauseaGastrointestinal disorders17/600/600/60
HeadacheNervous system disorders17/601/602/60
VomitingGastrointestinal disorders6/600/600/60
Abdominal discomfortGastrointestinal disorders3/600/600/60
Abdominal painGastrointestinal disorders2/600/601/60
DiarrhoeaGastrointestinal disorders2/600/602/60
ToothacheGastrointestinal disorders2/600/600/60
DizzinessNervous system disorders2/600/602/60
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders1/601/602/60
PalpitationsCardiac disorders1/600/600/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean32.7 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female28
Male32
08

Study locations

2 sites
  • Pfizer Clinical Research Unit
    Bruxelles, 1070, Belgium
  • Pfizer Clinical Research Unit
    Singapore, 188770, Singapore
09

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2007 to primary completion in Feb 2008, 3 months.

Results were first posted in Sep 2020, 12 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2012
First posted
Dec 6, 2012
StartActual
Oct 26, 2007
Primary completionActual
Feb 7, 2008
CompletionActual
Feb 9, 2008
Results first posted
Sep 16, 2020
Last update
Sep 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01743677
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 6, 2012
Start date
Oct 26, 2007
Primary completion
Feb 7, 2008
Completion
Feb 9, 2008
Results posted
Sep 16, 2020
Last update
Sep 16, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion